When History Has Its Eyes On You: Opill Vote Puts US FDA In Tough Spot
A unanimous US FDA advisory committee vote in favor of a landmark decision to make oral contraceptives available without a prescription should be history in the making. But the desire to make history – rather than address FDA’s significant concerns with the actual application for Perrigo’s Opill – seems to have carried the day.
You may also be interested in...
FDA’s approval of OTC counter oral contraceptive is milestone moment in public health, but not a straightforward regulatory decision.
The US FDA’s approval of an over-the-counter oral contraceptive is a milestone moment in public health, but it certainly isn’t a straightforward regulatory decision.
The US FDA took three high profile applications to an external advisory committee meeting during the week of 8 May – and offered a very skeptical read on the approvability of each. All three won positive votes from the committees, in no small part thanks to the messages delivered during the Open Public Hearings.